Brentuximab vedotin：复发或难治性CD30+淋巴瘤儿童的新希望

{"title":"Brentuximab vedotin：复发或难治性CD30+淋巴瘤儿童的新希望","authors":"Aurelie Cabannes Hamy","doi":"10.1684/hma.2019.1404","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":42476,"journal":{"name":"Hematologie","volume":null,"pages":null},"PeriodicalIF":0.1000,"publicationDate":"2018-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Brentuximab védotin : un nouvel espoir chez les enfants atteints de lymphome CD30+ en rechute ou réfractaire\",\"authors\":\"Aurelie Cabannes Hamy\",\"doi\":\"10.1684/hma.2019.1404\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":42476,\"journal\":{\"name\":\"Hematologie\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.1000,\"publicationDate\":\"2018-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hematologie\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1684/hma.2019.1404\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematologie","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1684/hma.2019.1404","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}